Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ION-464 by Ionis Pharmaceuticals for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration): Likelihood of Approval
ION-464 is under clinical development by Ionis Pharmaceuticals and currently in Phase II for Multiple System Atrophy (MSA or Shy-Drager...
Zilganersen sodium by Ionis Pharmaceuticals for Alexander Disease: Likelihood of Approval
Zilganersen sodium is under clinical development by Ionis Pharmaceuticals and currently in Phase III for Alexander Disease. According to GlobalData,...
Ulefnersen sodium by Ionis Pharmaceuticals for Amyotrophic Lateral Sclerosis: Likelihood of Approval
Ulefnersen sodium is under clinical development by Ionis Pharmaceuticals and currently in Phase III for Amyotrophic Lateral Sclerosis. According to...
Olezarsen sodium by Ionis Pharmaceuticals for Familial Chylomicronemia (Type I Hyperlipoproteinemia): Likelihood of Approval
Olezarsen sodium is under clinical development by Ionis Pharmaceuticals and currently in Pre-Registration for Familial Chylomicronemia (Type I Hyperlipoproteinemia). According...
Donidalorsen sodium by Ionis Pharmaceuticals for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency): Likelihood of Approval
Donidalorsen sodium is under clinical development by Ionis Pharmaceuticals and currently in Phase III for Hereditary Angioedema (HAE) (C1 Esterase...
Sapablursen sodium by Ionis Pharmaceuticals for Polycythemia Vera: Likelihood of Approval
Sapablursen sodium is under clinical development by Ionis Pharmaceuticals and currently in Phase II for Polycythemia Vera. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Ionis Pharmaceuticals's Evazarsen Sodium?
Evazarsen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase II program in Resistant Hypertension. According...
Risk adjusted net present value: What is the current valuation of Ionis Pharmaceuticals's Donidalorsen Sodium?
Donidalorsen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase III program in Hereditary Angioedema (HAE)...
Risk adjusted net present value: What is the current valuation of Ionis Pharmaceuticals's Sapablursen Sodium?
Sapablursen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase II program in Polycythemia Vera. According...